Matches in SemOpenAlex for { <https://semopenalex.org/work/W2290356236> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W2290356236 endingPage "34" @default.
- W2290356236 startingPage "34" @default.
- W2290356236 abstract "Everolimus is an orally administered inhibitor of the mammalian target of rapamycin (mTOR) recommended for patients with metastatic renal cell carcinoma (mRCC) who progressed on previous vascular endothelial growth factor (VEGF) receptor-tyrosine kinase inhibitor therapy. Efficacy of everolimus in patients who progressed on anti-VEGF monoclonal antibody bevacizumab is unknown. We did a multicenter prospective trial of everolimus in patients with mRCC whose disease had progressed on bevacizumab ± interferon alpha (IFN). Patients with clear-cell mRCC which had progressed on bevacizumab ± IFN received everolimus 10 mg once daily. The primary end point was the proportion of patients remaining progression-free for 56 days, and a two-stage Simon design was used, with 80 % power and an alpha risk of 5 %. This study is registered with ClinicalTrials.gov, number NCT02056587. From December 2011 to October 2013, a total of 37 patients (28 M, 9 F) were enrolled. Median age was 60.5 years (range 41-66), 11 % had Eastern Cooperative Oncology Group Performance Status (ECOG PS) > 2, and Memorial Sloan-Kettering Cancer Center (MSKCC) favorable/intermediate risk was 38/62 %. Five (14 %) patients had a confirmed partial response and 26 (70 %) patients had a stable disease. Median progression-free survival was 11.5 months (95 % CI, 8.8–14.2). Median overall survival was not reached. No grade 3 or 4 treatment-related toxicities were observed. The most common grade 2 adverse events were fatigue (19 %) and pneumonitis (8 %). Everolimus demonstrated a favorable toxicity profile and promising anti-tumor activity as a second-line therapy in metastatic renal cell carcinoma (RCC) patients previously treated with bevacizumab ± IFN." @default.
- W2290356236 created "2016-06-24" @default.
- W2290356236 creator A5009610086 @default.
- W2290356236 creator A5029456064 @default.
- W2290356236 creator A5051503045 @default.
- W2290356236 creator A5051970875 @default.
- W2290356236 creator A5067016795 @default.
- W2290356236 creator A5086314799 @default.
- W2290356236 creator A5090238053 @default.
- W2290356236 date "2015-06-19" @default.
- W2290356236 modified "2023-09-25" @default.
- W2290356236 title "Everolimus in patients with metastatic renal cell carcinoma previously treated with bevacizumab: a prospective multicenter study CRAD001LRU02T⃰" @default.
- W2290356236 doi "https://doi.org/10.17650/1726-9776-2015-11-2-34-39" @default.
- W2290356236 hasPublicationYear "2015" @default.
- W2290356236 type Work @default.
- W2290356236 sameAs 2290356236 @default.
- W2290356236 citedByCount "1" @default.
- W2290356236 countsByYear W22903562362018 @default.
- W2290356236 crossrefType "journal-article" @default.
- W2290356236 hasAuthorship W2290356236A5009610086 @default.
- W2290356236 hasAuthorship W2290356236A5029456064 @default.
- W2290356236 hasAuthorship W2290356236A5051503045 @default.
- W2290356236 hasAuthorship W2290356236A5051970875 @default.
- W2290356236 hasAuthorship W2290356236A5067016795 @default.
- W2290356236 hasAuthorship W2290356236A5086314799 @default.
- W2290356236 hasAuthorship W2290356236A5090238053 @default.
- W2290356236 hasBestOaLocation W22903562361 @default.
- W2290356236 hasConcept C126322002 @default.
- W2290356236 hasConcept C143998085 @default.
- W2290356236 hasConcept C168563851 @default.
- W2290356236 hasConcept C197934379 @default.
- W2290356236 hasConcept C203092338 @default.
- W2290356236 hasConcept C2775965419 @default.
- W2290356236 hasConcept C2776694085 @default.
- W2290356236 hasConcept C2777472916 @default.
- W2290356236 hasConcept C2777714996 @default.
- W2290356236 hasConcept C2777802072 @default.
- W2290356236 hasConcept C2779524853 @default.
- W2290356236 hasConcept C2779699572 @default.
- W2290356236 hasConcept C2992435398 @default.
- W2290356236 hasConcept C535046627 @default.
- W2290356236 hasConcept C71924100 @default.
- W2290356236 hasConcept C90924648 @default.
- W2290356236 hasConceptScore W2290356236C126322002 @default.
- W2290356236 hasConceptScore W2290356236C143998085 @default.
- W2290356236 hasConceptScore W2290356236C168563851 @default.
- W2290356236 hasConceptScore W2290356236C197934379 @default.
- W2290356236 hasConceptScore W2290356236C203092338 @default.
- W2290356236 hasConceptScore W2290356236C2775965419 @default.
- W2290356236 hasConceptScore W2290356236C2776694085 @default.
- W2290356236 hasConceptScore W2290356236C2777472916 @default.
- W2290356236 hasConceptScore W2290356236C2777714996 @default.
- W2290356236 hasConceptScore W2290356236C2777802072 @default.
- W2290356236 hasConceptScore W2290356236C2779524853 @default.
- W2290356236 hasConceptScore W2290356236C2779699572 @default.
- W2290356236 hasConceptScore W2290356236C2992435398 @default.
- W2290356236 hasConceptScore W2290356236C535046627 @default.
- W2290356236 hasConceptScore W2290356236C71924100 @default.
- W2290356236 hasConceptScore W2290356236C90924648 @default.
- W2290356236 hasIssue "2" @default.
- W2290356236 hasLocation W22903562361 @default.
- W2290356236 hasLocation W22903562362 @default.
- W2290356236 hasOpenAccess W2290356236 @default.
- W2290356236 hasPrimaryLocation W22903562361 @default.
- W2290356236 hasRelatedWork W1967154897 @default.
- W2290356236 hasRelatedWork W1994664208 @default.
- W2290356236 hasRelatedWork W1995193840 @default.
- W2290356236 hasRelatedWork W2010133921 @default.
- W2290356236 hasRelatedWork W2024586523 @default.
- W2290356236 hasRelatedWork W2037837794 @default.
- W2290356236 hasRelatedWork W2063672847 @default.
- W2290356236 hasRelatedWork W2081371466 @default.
- W2290356236 hasRelatedWork W2154171266 @default.
- W2290356236 hasRelatedWork W2290356236 @default.
- W2290356236 hasVolume "11" @default.
- W2290356236 isParatext "false" @default.
- W2290356236 isRetracted "false" @default.
- W2290356236 magId "2290356236" @default.
- W2290356236 workType "article" @default.